Skip to main content
Atrás
JAZZ logo

Jazz Pharmaceuticals plc

Calidad de datos: 100%
JAZZ
NASDAQ Healthcare Biotechnology
$185.01
▲ $2.69 (1.48%)
Cap. Mercado: 11.39B
Rango del Día
$180.68 $185.07
Rango de 52 Semanas
$95.49 $198.00
Volumen
1,476,713
Promedio 50D / 200D
$173.53 / $144.04
Cierre Anterior
$182.32

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -32.0 0.4
P/B 2.6 2.9
ROE % -8.5 3.9
Net Margin % -8.4 3.8
Rev Growth 5Y % 8.4 10.0
D/E 1.3 0.2

Precio Objetivo de Analistas

Hold
$207.86 +12.4%
Low: $170.00 High: $235.00
P/E Futuro
7.6
EPS Futuro
$23.93
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
4.4 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $31.98
$30.75 – $33.42
6 B 2
FY2029 $30.88
$29.69 – $32.27
5.8 B 2
FY2028 $26.64
$19.61 – $32.84
5.2 B 4

Puntos Clave

Revenue grew 8.37% annually over 5 years — modest growth
Earnings declined -163.58% over the past year
Generating 1.30B in free cash flow
PEG of 0.18 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.49%
Capital efficient — spends only 1.38% of revenue on capex

Crecimiento

Revenue Growth (5Y)
8.37%
Revenue (1Y)4.88%
Earnings (1Y)-163.58%
FCF Growth (3Y)10.20%

Calidad

Return on Equity
-8.47%
ROIC1.73%
Net Margin-8.35%
Op. Margin5.26%

Seguridad

Debt / Equity
1.26
Current Ratio1.86
Interest Coverage1.15

Valoración

P/E Ratio
-31.98
P/B Ratio2.64
EV/EBITDA68.72
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4.88% Revenue Growth (3Y) 5.50%
Earnings Growth (1Y) -163.58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8.37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.27B Net Income (TTM) -356.15M
ROE -8.47% ROA -3.05%
Gross Margin 88.21% Operating Margin 5.26%
Net Margin -8.35% Free Cash Flow (TTM) 1.30B
ROIC 1.73% FCF Growth (3Y) 10.20%
Safety
Debt / Equity 1.26 Current Ratio 1.86
Interest Coverage 1.15 Dividend Yield 0.00%
Valuation
P/E Ratio -31.98 P/B Ratio 2.64
P/S Ratio 2.67 PEG Ratio 0.18
EV/EBITDA 68.72 Dividend Yield 0.00%
Market Cap 11.39B Enterprise Value 15.42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.27B 4.07B 3.83B 3.66B 3.09B
Net Income -356.15M 560.12M 414.83M -224.06M -328.95M
EPS (Diluted) -5.84 8.65 6.10 -3.58 -5.51
Gross Profit 3.76B 3.62B 3.40B 3.12B 2.65B
Operating Income 224.42M 716.63M 578.58M -65.53M 170.28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11.66B 12.01B 11.39B 10.84B 12.30B
Total Liabilities 7.34B 7.92B 7.66B 7.75B 8.33B
Shareholders' Equity 4.32B 4.09B 3.74B 3.09B 3.97B
Total Debt 5.42B 6.16B 5.79B 5.81B 6.15B
Cash & Equivalents 1.39B 2.41B 1.51B 881.48M 591.45M
Current Assets 4.17B 4.63B 3.44B 2.61B 2.61B
Current Liabilities 2.24B 1.04B 1.54B 933.19M 809.30M